U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Google Secures Pentagon AI Deal for Classified Projects 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
MONTREAL, Feb. 17, 2016 -- Ropack Pharma Solutions (RPS), provider of high-quality drug development, manufacturing and packaging of solid oral dosage, has hired Francois Chouinard, Ph.D., as Director of Business Development for R&D and Formulation. Chouinard will report to Paul Dupont, VP, Marketing and Business Development.
|
|||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/19f7d496-d231-4eab-b156-2d28fa040660
Chouinard, who holds a doctorate in Pharmaceutical Sciences, will focus on business development for the drug development facilities in Long Island, New York, purchased by RPS and most recently operated by Forest Labs. “Francois brings a deep understanding of the drug development process,” said Dupont. “His many years of success and experience working in the CDMO/CMO environment, along with his superior customer engagement skills and scientific background, are unique and valuable assets which will advance and support our mission to provide a superior customer engagement experience.”
An internationally experienced Pharma R&D leader, he brings more than 20 years of experience in the generic, contract development and biotech industries, developing more than 30 solid dose products for the Canadian and European markets. Prior to joining RPS, he was Executive Director of Product Development at Halo Pharmaceutical’s Montreal location where he was actively involved in the development of new business opportunities as well as the management of all product development.
“With Ropack Pharma Solutions now providing a complete range of contract development services, my product development experience in brand and generic Pharma will help RPS support the best development strategy for our customers and establish a high level of confidence in our ability to meet their timelines and product quality attributes,” noted Chouinard.
About Ropack Pharma Solutions
Ropack Pharma Solutions (RPS) supports solid oral dosage projects from early-stage formulation through clinical manufacturing, packaging, distribution and commercial manufacturing and packaging. Facilities in Montreal, Canada, and Long Island, New York, are cGMP-compliant, site-licensed by the FDA and Health Canada-certified.
Contact Paul Dupont Ropack Pharma Solutions 10801 Mirabeau, Montréal, Québec H1J 1T7, CANADA 514-353-7000 [email protected]
